{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:57:06Z","timestamp":1777424226919,"version":"3.51.4"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Purpose:<\/jats:bold> Patients with osteoporosis are at an increased risk of cardiovascular disease (CVD). Several antiosteoporosis medications have been demonstrated with the benefit of preventing osteoporosis. Our aim is to assess the CVD risks associated with antiosteoporosis medications using the National Health Insurance Research Database in Taiwan between 2000 and 2016.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Among 41,102 patients of 40+ years old with newly diagnosed osteoporosis, 69.1% (N = 28,387) of patients were included in the user cohort of antiosteoporosis medicines, of whom 13, 472 developed CVD by the end of 2016, while 14,915 did not. Using the nested case\u2013control analysis in the user cohort (88.0% women and 77.4% elderly), we applied conditional logistic regression to estimate odds ratios (ORs) of eight types of CVD for the users of denosumab, bisphosphonate, teriparatide, and hormone replacement therapy (HRT).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The adjusted ORs of overall CVDs were 0.13 (95% CI: 0.12\u20130.15) for denosumab users, 0.52 (95% CI: 0.45\u20130.61) for teriparatide users, and 0.80 (95% CI: 0.76\u20130.85) for bisphosphonate users. The HRT users were at higher odds of coronary artery and peripheral artery diseases, heart failure, pulmonary embolism, and deep vein thrombosis.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Denosumab, teriparatide, and bisphosphonate may have more protective effects against CVD than hormone therapy. Physicians may take subsequent cardiovascular risks into account when choosing an adequate antiosteoporosis medication for patients with osteoporosis.<\/jats:p>","DOI":"10.3389\/fphar.2023.1220174","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T04:57:43Z","timestamp":1696913863000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Antiosteoporosis medications and cardiovascular disease: a population-based nationwide nested case\u2013control study"],"prefix":"10.3389","volume":"14","author":[{"given":"Wen-Hsuan","family":"Tsai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fung-Chang","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Hsin","family":"Muo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chieh","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-I.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1507\/endocrj.k07e-123","article-title":"Endogenous intact PTH is suppressed during Teriparatide (rhPTH 1-34) administration in postmenopausal women with established osteoporosis","volume":"55","author":"Anastasilakis","year":"2008","journal-title":"Endocr. J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/00019501-199809080-00007","article-title":"Serum concentration of calcium, 1,25 vitamin D and parathyroid hormone are not correlated with coronary calcifications. An electron beam computed tomography study","volume":"9","author":"Arad","year":"1998","journal-title":"Coron. artery Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00198-011-1546-9","article-title":"Alendronate and atrial fibrillation: A meta-analysis of randomized placebo-controlled clinical trials","volume":"23","author":"Barrett-Connor","year":"2012","journal-title":"Osteoporos. Int."},{"key":"B4","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1191\/0961203305lu2219oa","article-title":"Bisphosphonates and atherosclerosis: Why?","volume":"14","author":"Bevilacqua","year":"2005","journal-title":"Lupus"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.31729\/jnma.5444","article-title":"Use of statins as lipid lowering agent in hypercholesterolemia in a tertiary care hospital: A descriptive cross-sectional study","volume":"58","author":"Bhattarai","year":"2020","journal-title":"JNMA J. Nepal Med. Assoc."},{"key":"B6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ijcard.2009.11.041","article-title":"Bisphosphonate use in women and the risk of atrial fibrillation: A systematic review and meta-analysis","volume":"142","author":"Bhuriya","year":"2010","journal-title":"Int. J. Cardiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.03.021","article-title":"Association between the cumulative exposure to bisphosphonates and hospitalization for atherosclerotic cardiovascular events: A population-based study","volume":"301","author":"Casula","year":"2020","journal-title":"Atherosclerosis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000347145","article-title":"Cinacalcet improves endothelial dysfunction and cardiac hypertrophy in patients on hemodialysis with secondary hyperparathyroidism","volume":"122","author":"Choi","year":"2012","journal-title":"Nephron Clin. Pract."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1161\/01.RES.0000149165.99974.12","article-title":"Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin","volume":"95","author":"Collin-Osdoby","year":"2004","journal-title":"Circulation Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1210\/clinem\/dgaa450","article-title":"Cardiovascular safety of abaloparatide in postmenopausal women with osteoporosis: Analysis from the ACTIVE phase 3 trial","volume":"105","author":"Cosman","year":"2020","journal-title":"J. Clin. Endocrinol. metabolism"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1056\/NEJMc076132","article-title":"Alendronate and atrial fibrillation","volume":"356","author":"Cummings","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1210\/jc.2015-4181","article-title":"Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study","volume":"101","author":"Dempster","year":"2016","journal-title":"J. Clin. Endocrinol. metabolism"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s10741-021-10153-2","article-title":"Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases","volume":"27","author":"Dutka","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e506","DOI":"10.1161\/CIR.0000000000000912","article-title":"Menopause transition and cardiovascular disease risk: Implications for timing of early prevention: A scientific statement from the American heart association","volume":"142","author":"El Khoudary","year":"2020","journal-title":"Circulation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.jacc.2010.05.050","article-title":"Bisphosphonate use and prevalence of valvular and vascular calcification in women MESA (the multi-ethnic study of atherosclerosis)","volume":"56","author":"Elmariah","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11657-019-0672-4","article-title":"No impact of anti-rank ligand and PTH analogs on cardiovascular risk in postmenopausal osteoporosis: A systematic literature review and meta-analysis","volume":"15","author":"Ferrieres","year":"2020","journal-title":"Archives Osteoporos."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/2071300b0","article-title":"Inhibition of aortic calcification by means of pyrophosphate and polyphosphates","volume":"207","author":"Fleisch","year":"1965","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s40265-020-01364-2","article-title":"Assessment of cardiovascular safety of anti-osteoporosis drugs","volume":"80","author":"Fuggle","year":"2020","journal-title":"Drugs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1089\/jwh.2006.15.35","article-title":"Hormone therapy and coronary heart disease: The role of time since menopause and age at hormone initiation","volume":"15","author":"Grodstein","year":"2006","journal-title":"J. women's health"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa1505241","article-title":"Vascular effects of early versus late postmenopausal treatment with estradiol","volume":"374","author":"Hodis","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2165\/11584720-000000000-00000","article-title":"Impact of bisphosphonates on the risk of atrial fibrillation","volume":"10","author":"Howard","year":"2010","journal-title":"Am. J. Cardiovasc. drugs drugs, devices, other interventions"},{"key":"B24","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3390\/jcm8070932","article-title":"Comparison of the effects of denosumab and alendronate on cardiovascular and renal outcomes in osteoporotic patients","volume":"8","author":"Hsu","year":"2019","journal-title":"J. Clin. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2008.10.043","article-title":"The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-\/-) mice","volume":"205","author":"Ivanovski","year":"2009","journal-title":"Atherosclerosis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1007\/s00198-012-1894-0","article-title":"A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke","volume":"23","author":"Kang","year":"2012","journal-title":"Osteoporos. Int."},{"key":"B27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00198-012-2213-5","article-title":"Bisphosphonates reduced the risk of acute myocardial infarction: A 2-year follow-up study","volume":"24","author":"Kang","year":"2013","journal-title":"Osteoporos. Int."},{"key":"B28","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1056\/NEJMc071514","article-title":"Yearly zoledronic acid in postmenopausal osteoporosis","volume":"357","author":"Karam","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/ki.2008.407","article-title":"Cinacalcet suppresses calcification of the aorta and heart in uremic rats","volume":"74","author":"Kawata","year":"2008","journal-title":"Kidney Int."},{"key":"B30","doi-asserted-by":"publisher","first-page":"20631","DOI":"10.1038\/s41598-020-77534-9","article-title":"A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases","volume":"10","author":"Kim","year":"2020","journal-title":"Sci. Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"R30","DOI":"10.1186\/ar2938","article-title":"Bisphosphonates and risk of atrial fibrillation: A meta-analysis","volume":"12","author":"Kim","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3892\/ijmm.2016.2582","article-title":"Zoledronic acid suppresses transforming growth factor-\u03b2-induced fibrogenesis by human gingival fibroblasts","volume":"38","author":"Komatsu","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3109\/13697137.2014.992011","article-title":"Cardiovascular safety of conjugated estrogens plus bazedoxifene: meta-analysis of the SMART trials","volume":"18","author":"Komm","year":"2015","journal-title":"Climacteric J. Int. Menopause Soc."},{"key":"B34","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2016.06.039","article-title":"Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis","volume":"252","author":"Kranenburg","year":"2016","journal-title":"Atherosclerosis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1007\/s00198-009-1143-3","article-title":"Use of oral bisphosphonates and risk of venous thromboembolism: A population-based case-control study","volume":"21","author":"Lamberg","year":"2010","journal-title":"Osteoporos. Int."},{"key":"B36","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/j.1742-1241.2010.02335.x","article-title":"Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials","volume":"64","author":"Lewiecki","year":"2010","journal-title":"Int. J. Clin. Pract."},{"key":"B37","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2165\/00002018-200932030-00004","article-title":"Bisphosphonates and atrial fibrillation: Systematic review and meta-analysis","volume":"32","author":"Loke","year":"2009","journal-title":"Drug Saf."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/ki.2013.521","article-title":"Vascular calcification is dependent on plasma levels of pyrophosphate","volume":"85","author":"Lomashvili","year":"2014","journal-title":"Kidney Int."},{"key":"B40","doi-asserted-by":"publisher","first-page":"115121","DOI":"10.1016\/j.bone.2019.115121","article-title":"Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta-analysis","volume":"130","author":"Lv","year":"2020","journal-title":"Bone"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/1471-2474-10-113","article-title":"Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies","volume":"10","author":"Mak","year":"2009","journal-title":"BMC Musculoskelet. Disord."},{"key":"B43","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jama.2022.13044","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement","volume":"328","author":"Mangione","year":"2022","journal-title":"Jama"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.amjcard.2005.06.034","article-title":"Usefulness of bone mineral density to predict significant coronary artery disease","volume":"96","author":"Marcovitz","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"680","DOI":"10.7326\/0003-4819-136-9-200205070-00011","article-title":"Postmenopausal estrogen replacement and risk for venous thromboembolism: A systematic review and meta-analysis for the U.S. Preventive services task force","volume":"136","author":"Miller","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3109\/10611869409015910","article-title":"Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro","volume":"2","author":"M\u00f6nkk\u00f6nen","year":"1994","journal-title":"J. drug Target."},{"key":"B47","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12902-015-0077-3","article-title":"Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: A short-term study","volume":"15","author":"Nakamura","year":"2015","journal-title":"BMC Endocr. Disord."},{"key":"B48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijcard.2016.11.099","article-title":"Arterial calcification: A new perspective?","volume":"228","author":"Nicoll","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1359\/jbmr.091201","article-title":"Atrial fibrillation and bisphosphonate therapy","volume":"25","author":"Pazianas","year":"2010","journal-title":"J. bone mineral Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1007\/s00198-017-4213-y","article-title":"Excess risk of venous thromboembolism in hip fracture patients and the prognostic impact of comorbidity","volume":"28","author":"Pedersen","year":"2017","journal-title":"Osteoporos. Int."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1093\/eurheartj\/ehq109","article-title":"Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography","volume":"31","author":"Pilz","year":"2010","journal-title":"Eur. heart J."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e10522","DOI":"10.1002\/jbm4.10522","article-title":"Cardiovascular safety of antifracture medications in patients with osteoporosis: A narrative review of evidence from randomized studies","volume":"5","author":"Rodr\u00edguez","year":"2021","journal-title":"JBMR plus"},{"key":"B54","doi-asserted-by":"publisher","first-page":"dgaa481","DOI":"10.1210\/clinem\/dgaa481","article-title":"Oral bisphosphonate use reduces cardiovascular events in a cohort of Danish patients referred for bone mineral density","volume":"105","author":"Rodr\u00edguez","year":"2020","journal-title":"J. Clin. Endocrinol. metabolism"},{"key":"B55","doi-asserted-by":"publisher","first-page":"116647","DOI":"10.1016\/j.bone.2022.116647","article-title":"Cardiac adverse events in bisphosphonate and teriparatide users: An international pharmacovigilance study","volume":"168","author":"Rodr\u00edguez","year":"2023","journal-title":"Bone"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12018-018-9251-2","article-title":"Exploring the links between common diseases of ageing\u2014osteoporosis, sarcopenia and vascular calcification","volume":"17","author":"Rodriguez","year":"2019","journal-title":"Clin. Rev. Bone Mineral Metabolism"},{"key":"B57","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis-an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1161\/01.ATV.0000204334.48195.6a","article-title":"Enhanced T-cell expression of RANK ligand in acute coronary syndrome: Possible role in plaque destabilization","volume":"26","author":"Sandberg","year":"2006","journal-title":"Arteriosclerosis, thrombosis, Vasc. Biol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1042\/bj3100439","article-title":"Parathyroid hormone induces protein kinase C but not adenylate cyclase in adult cardiomyocytes and regulates cyclic AMP levels via protein kinase C-dependent phosphodiesterase activity","volume":"310","author":"Schl\u00fcter","year":"1995","journal-title":"Biochem. J."},{"key":"B61","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jbmr.4157","article-title":"Cardiovascular safety of denosumab across multiple indications: A systematic review and meta-analysis of randomized trials","volume":"36","author":"Seeto","year":"2021","journal-title":"J. bone mineral Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1378\/chest.13-0675","article-title":"Risk of serious atrial fibrillation and stroke with use of bisphosphonates: Evidence from a meta-analysis","volume":"144","author":"Sharma","year":"2013","journal-title":"Chest"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.amjcard.2014.03.008","article-title":"Risk of atrial fibrillation with use of oral and intravenous bisphosphonates","volume":"113","author":"Sharma","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ekir.2020.12.002","article-title":"Denosumab recovers aortic arch calcification during long-term hemodialysis","volume":"6","author":"Suzuki","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1359\/JBMR.050711","article-title":"Relationship between osteoporosis and cardiovascular disease in postmenopausal women","volume":"20","author":"Tank\u00f3","year":"2005","journal-title":"J. bone mineral Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.thromres.2017.05.015","article-title":"Venous thromboembolism in the elderly: A narrative review","volume":"155","author":"Tritschler","year":"2017","journal-title":"Thrombosis Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.amjcard.2007.12.013","article-title":"Relation of bone mineral density to frequency of coronary heart disease","volume":"101","author":"Varma","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s00223-011-9549-2","article-title":"Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: Calcium in the vessels and not the bones?","volume":"90","author":"Vestergaard","year":"2012","journal-title":"Calcif. tissue Int."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00198-009-1091-y","article-title":"Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism","volume":"21","author":"Vestergaard","year":"2010","journal-title":"Osteoporos. Int."},{"key":"B70","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s0002-9343(99)00028-5","article-title":"The association between low bone mass at the menopause and cardiovascular mortality","volume":"106","author":"von der Recke","year":"1999","journal-title":"Am. J. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/jbmr.1792","article-title":"Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis","volume":"28","author":"Wolfe","year":"2013","journal-title":"J. bone mineral Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1016\/j.ijcard.2013.11.105","article-title":"Cinacalcet ameliorates cardiac fibrosis in uremic hearts through suppression of endothelial-to-mesenchymal transition","volume":"171","author":"Wu","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.biocel.2012.12.016","article-title":"Inhibition of farnesyl pyrophosphate synthase attenuates angiotensin II-induced cardiac hypertrophy and fibrosis in vivo","volume":"45","author":"Yang","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jphs.2015.10.006","article-title":"Alendronate prevents angiotensin II-induced collagen I production through geranylgeranylation-dependent RhoA\/Rho kinase activation in cardiac fibroblasts","volume":"129","author":"Ye","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/s0306-3623(01)00121-5","article-title":"Bisphosphonates and atherosclerosis","volume":"35","author":"Ylitalo","year":"2000","journal-title":"General Pharmacol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00223-017-0319-7","article-title":"Etelcalcetide, A novel calcimimetic, prevents vascular calcification in A rat model of renal insufficiency with secondary hyperparathyroidism","volume":"101","author":"Yu","year":"2017","journal-title":"Calcif. tissue Int."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1220174\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T04:57:47Z","timestamp":1696913867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1220174\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":76,"alternative-id":["10.3389\/fphar.2023.1220174"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1220174","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]},"article-number":"1220174"}}